Estrogen Receptor Modulators
"Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure.
| Descriptor ID |
D020847
|
| MeSH Number(s) |
D06.347.360 D27.505.696.399.450.360
|
| Concept/Terms |
Estrogen Receptor Modulators- Estrogen Receptor Modulators
- Modulators, Estrogen Receptor
- Receptor Modulators, Estrogen
- Antiestrogens
- Antiestrogen
- Estrogen Receptor Modulator
- Modulator, Estrogen Receptor
- Receptor Modulator, Estrogen
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Estrogen Receptor Modulators" by people in this website by year, and whether "Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 6 | 1 | 7 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 2 | 3 |
| 2003 | 5 | 5 | 10 |
| 2004 | 3 | 1 | 4 |
| 2005 | 5 | 1 | 6 |
| 2006 | 3 | 3 | 6 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 3 | 4 |
| 2011 | 3 | 4 | 7 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estrogen Receptor Modulators" by people in Profiles.
-
Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models. Cancer Prev Res (Phila). 2023 02 06; 16(2):65-73.
-
Repurposing Antiestrogens for Tumor Immunotherapy. Cancer Discov. 2017 01; 7(1):17-19.
-
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2016 Feb 15; 22(4):935-47.
-
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. Clin Cancer Res. 2016 Jan 15; 22(2):301-9.
-
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J Clin Invest. 2014 Dec; 124(12):5490-502.
-
Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. J Natl Cancer Inst. 2014 Oct; 106(10).
-
A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur J Cancer. 2014 Nov; 50(16):2866-76.
-
The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. Steroids. 2014 Nov; 90:3-12.
-
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells. J Med Chem. 2014 Jun 12; 57(11):4569-83.
-
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014 Jan; 106(1):djt337.